---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039822"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:35:13.110643+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q2 net loss $98.5M; RLY-2608 dose expansion initiated with 86% CBR

## Summary
- Net loss of $98.5M ($0.81/share) in Q2 2023, up from $76.8M loss ($0.71) in Q2 2022; R&D expenses rose to $88.2M.
- Cash and investments $871.6M as of June 30, 2023; expected to fund operations into H2 2025.
- Initiated RLY-2608 600mg BID + fulvestrant dose expansion; interim CBR 86% (6/7 evaluable pts) with 1 partial response.
- No Grade 3+ hyperglycemia/diarrhea or AE-related discontinuations across 43 breast cancer patients; next data update in 2024.
- Anticipated milestones: RLY-4008 pivotal cohort enrollment H2 2023, ERα degrader candidate nomination 2023, RLY-2139 start early 2024.

## SEC filing metadata
- accession: 0000950170-23-039822
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/0000950170-23-039822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/rlay-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039822
- JSON: https://secwatch.observer/filing/0000950170-23-039822.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039822.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $98.5 million, EPS net loss per share of $0.81.
  - Period: second quarter 2023
  - Net income: Net loss was $98.5 million
  - EPS: net loss per share of $0.81
  - Result: reported results
  source text: Net loss was $98.5 million for the second quarter of 2023, or a net loss per share of $0.81
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/0000950170-23-039822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.